Latest Quarter
2026-03-31
Estrella Immunopharma Inc (ESLAW)
Revenue
$0.0
Net Income
-$2.3M
Operating Margin
N/A
Free Cash Flow
-$1.8M
Debt / Assets
95.4%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 891,789 | 550,737 | 424,447 | 444,530 |
| Operating Expenses | 2,292,064 | 3,376,737 | 3,949,447 | 469,530 |
| Operating Income | -2,292,064 | -3,376,737 | -3,949,447 | -469,530 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Income Before Tax | -2,292,064 | -3,376,737 | -3,949,447 | -469,530 |
| Income Tax Expense | 0 | 0 | 1,625 | 39,586 |
| Net Income | -2,292,064 | -3,376,737 | -3,951,072 | -469,530 |
| Per Share | ||||
| EPS | -0.05 | -0.09 | -0.11 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2025-12-31 | 2024-06-30 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Expenses | ||
| R&D Expenses | 0 | 0 |
| SG&A Expenses | 2,814,129 | 3,201,173 |
| Operating Expenses | 13,062,674 | 7,310,098 |
| Operating Income | -13,062,674 | -7,310,098 |
| Interest Expense | 0 | 0 |
| Income Before Tax | -13,062,674 | -7,310,098 |
| Income Tax Expense | 838 | 1,625 |
| Net Income | -13,063,512 | -7,311,723 |
| Per Share | ||
| EPS | -0.35 | -0.21 |
| EPS Diluted | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2024-12-31 | 2024-06-30 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 916,916 | 4,165,428 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 0 | 288,761 |
| Inventory | 0 | -288,761 |
| Total Current Assets | 1,640,777 | 4,454,189 |
| Property Plant Equipment | 0 | 0 |
| Goodwill and Intangibles | 0 | 0 |
| Total Assets | 3,140,777 | 4,454,189 |
| Liabilities | ||
| Account Payables | 0 | 0 |
| Short Term Debt | 0 | 0 |
| Total Current Liabilities | 2,997,046 | 180,701 |
| Long Term Debt | 0 | 0 |
| Total Liabilities | 2,997,046 | 180,701 |
| Shareholders Equity | ||
| Retained Earnings | -23,927,303 | -19,500,276 |
| Total Shareholders Equity | 143,731 | 4,273,488 |
| Balance Sheet (Annual) | 2024-12-31 | 2024-06-30 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 916,916 | 4,165,428 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 0 | 288,761 |
| Inventory | 0 | -288,761 |
| Total Current Assets | 1,640,777 | 4,454,189 |
| Property Plant Equipment | 0 | 0 |
| Goodwill and Intangibles | 0 | 0 |
| Total Assets | 3,140,777 | 4,454,189 |
| Liabilities | ||
| Account Payables | 0 | 0 |
| Short Term Debt | 0 | 0 |
| Total Current Liabilities | 2,997,046 | 180,701 |
| Long Term Debt | 0 | 0 |
| Total Liabilities | 2,997,046 | 180,701 |
| Shareholders Equity | ||
| Retained Earnings | -23,927,303 | -19,500,276 |
| Total Shareholders Equity | 143,731 | 4,273,488 |
| Cash Flow Statement (Quarterly) | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -13,063,512 | -8,847,629 | -7,311,723 |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock Based Compensation | 0 | 0 | 1,194,653 |
| Change in Working Capital | 10,620,670 | 775,700 | -9,951,236 |
| Operating Cash Flow | -1,785,679 | -7,639,673 | -16,068,306 |
| Investing Activities | |||
| Capital Expenditure | 0 | -1 | -4 |
| Investments | 0 | 3 | -4 |
| Investing Cash Flow | 0 | 0 | 4,960,647 |
| Financing Activities | |||
| Debt Repayment | 0 | -10,000,000 | 0 |
| Common Stock Issued/Repurchased | 2,370,538 | -489,426 | 8,665,560 |
| Dividends Paid | 0 | 0 | 0 |
| Financing Cash Flow | 2,253,065 | -489,426 | 12,793,941 |
| Summary | |||
| Free Cash Flow | -1,785,680 | -7,639,674 | -16,068,310 |
| Net Change in Cash | 467,386 | -8,129,099 | 1,686,282 |
| Cash Flow Statement (Annual) | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -13,063,512 | -8,847,629 | -7,311,723 |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock Based Compensation | 0 | 0 | 1,194,653 |
| Change in Working Capital | 10,620,670 | 775,700 | -9,951,236 |
| Operating Cash Flow | -1,785,679 | -7,639,673 | -16,068,306 |
| Investing Activities | |||
| Capital Expenditure | 0 | -1 | -4 |
| Investments | 0 | 3 | -4 |
| Investing Cash Flow | 0 | 0 | 4,960,647 |
| Financing Activities | |||
| Debt Repayment | 0 | -10,000,000 | 0 |
| Common Stock Issued/Repurchased | 2,370,538 | -489,426 | 8,665,560 |
| Dividends Paid | 0 | 0 | 0 |
| Financing Cash Flow | 2,253,065 | -489,426 | 12,793,941 |
| Summary | |||
| Free Cash Flow | -1,785,680 | -7,639,674 | -16,068,310 |
| Net Change in Cash | 467,386 | -8,129,099 | 1,686,282 |